Mineralys Therapeutics completes enrollment in Explore-CKD Phase 2 trial
Mineralys Therapeutics (MLYS) has completed enrollment in the Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorundrostat for ...
Scientists design an effective treatment strategy to prevent heart injury caused by a class of anticancer drugs
A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with international partners, has designed a strategy for preventing the cardiotoxic ...
Armed robbery in Revesby3h
Scientists Craft Heart-Safe Strategy for Cancer Drugs
A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...
Neurology Advisor8h
GLP-1 Receptor Agonists Tied to Risks and Benefits Beyond Weight Loss
For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.
Pharmabiz12h
Akums combines two potent diabetes medicines for enhanced treatment efficacy
Akums combines two potent diabetes medicines for enhanced treatment efficacy: Our Bureau, Bengaluru Tuesday, February 4, 2025, 15:30 Hrs [IST] Akums Drugs and Pharmaceuticals, a l ...
New Therapeutic Target Discovered for Lethal Form of Heart Failure
Researchers discovered that ALPK2, a heart-specific enzyme, may protect against HFpEF by activating TPM1 in heart muscle ...
Mineralys completes enrollment for hypertension drug trial
RADNOR, Pa. - Mineralys Therapeutics , Inc. (NASDAQ:MLYS), a biopharmaceutical company specializing in the development of treatments for cardiovascular and kidney diseases, has announced the ...